Cargando…

Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer

Background: Chromobox family proteins (CBXs) are vital components of epigenetic regulation complexes and transcriptionally inhibit target genes by modifying the chromatin. Accumulating evidence indicates that CBXs are involved in the initiation and progression of multiple malignancies. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Xuefen, Wang, Junjun, Chen, Jiabing, Zhuang, Mingkai, Huang, Tingxuan, Chen, Zhixin, Huang, Yuehong, Zheng, Biyun, Wang, Xiaozhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019303/
https://www.ncbi.nlm.nih.gov/pubmed/35464847
http://dx.doi.org/10.3389/fgene.2022.851390
_version_ 1784689231912763392
author Fang, Xuefen
Wang, Junjun
Chen, Jiabing
Zhuang, Mingkai
Huang, Tingxuan
Chen, Zhixin
Huang, Yuehong
Zheng, Biyun
Wang, Xiaozhong
author_facet Fang, Xuefen
Wang, Junjun
Chen, Jiabing
Zhuang, Mingkai
Huang, Tingxuan
Chen, Zhixin
Huang, Yuehong
Zheng, Biyun
Wang, Xiaozhong
author_sort Fang, Xuefen
collection PubMed
description Background: Chromobox family proteins (CBXs) are vital components of epigenetic regulation complexes and transcriptionally inhibit target genes by modifying the chromatin. Accumulating evidence indicates that CBXs are involved in the initiation and progression of multiple malignancies. However, the expression, function, and clinical relevance such as the prognostic and diagnostic values of different CBXs in esophageal carcinoma (ESCA) are still unclear. Methods: We applied Oncomine, TCGA, GEO, GEPIA, UALCAN, Kaplan–Meier plotter, cBioPortal, Metascape, and TIMER to investigate the roles of CBX family members in ESCA. Additionally, quantitative real-time PCR (RT-PCR), western blot, and immunofluorescence were used to verify the expression of CBX family members in ESCA clinical samples. Results: Compared with normal tissues, the mRNA expression levels of CBX1/3/8 were significantly increased in ESCA, whereas CBX7 mRNA expression was reduced in both the TCGA cohort and GEO cohort. In the TCGA cohort, ROC curves suggested that CBX1/2/3/4/8 had great diagnostic value in ESCA, and the AUCs were above 0.9. Furthermore, upregulation of CBX1/3/8 and downregulation of CBX7 were closely related to the clinicopathological parameters in ESCA patients, such as tumor grades, tumor nodal metastasis status, and TP53 mutation status. The survival analysis indicated that higher CBX1/3/8 mRNA expressions and lower CBX7 expression suggested an unfavorable prognosis in ESCA. High genetic change rate (52%) of CBXs was found in ESCA patients. Functions and pathways of mutations in CBXs and their 50 frequently altered neighbor genes in ESCA patients were investigated; the results showed that DNA repair and DNA replication were correlated to CBX alterations. Moreover, we found a significant correlation between the expression level of CBX family members and the infiltration of immune cells in ESCA. Finally, we verified the expression of CBX family members in clinical samples and found the results were consistent with the databases. Conclusion: Our study implied that CBX1/3/7/8 are potential targets of precision therapy for ESCA patients and new biomarkers for the prognosis.
format Online
Article
Text
id pubmed-9019303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90193032022-04-21 Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer Fang, Xuefen Wang, Junjun Chen, Jiabing Zhuang, Mingkai Huang, Tingxuan Chen, Zhixin Huang, Yuehong Zheng, Biyun Wang, Xiaozhong Front Genet Genetics Background: Chromobox family proteins (CBXs) are vital components of epigenetic regulation complexes and transcriptionally inhibit target genes by modifying the chromatin. Accumulating evidence indicates that CBXs are involved in the initiation and progression of multiple malignancies. However, the expression, function, and clinical relevance such as the prognostic and diagnostic values of different CBXs in esophageal carcinoma (ESCA) are still unclear. Methods: We applied Oncomine, TCGA, GEO, GEPIA, UALCAN, Kaplan–Meier plotter, cBioPortal, Metascape, and TIMER to investigate the roles of CBX family members in ESCA. Additionally, quantitative real-time PCR (RT-PCR), western blot, and immunofluorescence were used to verify the expression of CBX family members in ESCA clinical samples. Results: Compared with normal tissues, the mRNA expression levels of CBX1/3/8 were significantly increased in ESCA, whereas CBX7 mRNA expression was reduced in both the TCGA cohort and GEO cohort. In the TCGA cohort, ROC curves suggested that CBX1/2/3/4/8 had great diagnostic value in ESCA, and the AUCs were above 0.9. Furthermore, upregulation of CBX1/3/8 and downregulation of CBX7 were closely related to the clinicopathological parameters in ESCA patients, such as tumor grades, tumor nodal metastasis status, and TP53 mutation status. The survival analysis indicated that higher CBX1/3/8 mRNA expressions and lower CBX7 expression suggested an unfavorable prognosis in ESCA. High genetic change rate (52%) of CBXs was found in ESCA patients. Functions and pathways of mutations in CBXs and their 50 frequently altered neighbor genes in ESCA patients were investigated; the results showed that DNA repair and DNA replication were correlated to CBX alterations. Moreover, we found a significant correlation between the expression level of CBX family members and the infiltration of immune cells in ESCA. Finally, we verified the expression of CBX family members in clinical samples and found the results were consistent with the databases. Conclusion: Our study implied that CBX1/3/7/8 are potential targets of precision therapy for ESCA patients and new biomarkers for the prognosis. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019303/ /pubmed/35464847 http://dx.doi.org/10.3389/fgene.2022.851390 Text en Copyright © 2022 Fang, Wang, Chen, Zhuang, Huang, Chen, Huang, Zheng and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Fang, Xuefen
Wang, Junjun
Chen, Jiabing
Zhuang, Mingkai
Huang, Tingxuan
Chen, Zhixin
Huang, Yuehong
Zheng, Biyun
Wang, Xiaozhong
Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title_full Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title_fullStr Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title_full_unstemmed Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title_short Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer
title_sort identification and validation of chromobox family members as potential prognostic biomarkers and therapeutic targets for human esophageal cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019303/
https://www.ncbi.nlm.nih.gov/pubmed/35464847
http://dx.doi.org/10.3389/fgene.2022.851390
work_keys_str_mv AT fangxuefen identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT wangjunjun identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT chenjiabing identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT zhuangmingkai identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT huangtingxuan identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT chenzhixin identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT huangyuehong identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT zhengbiyun identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer
AT wangxiaozhong identificationandvalidationofchromoboxfamilymembersaspotentialprognosticbiomarkersandtherapeutictargetsforhumanesophagealcancer